BE2013C023I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C023I2
BE2013C023I2 BE2013C023C BE2013C023C BE2013C023I2 BE 2013C023 I2 BE2013C023 I2 BE 2013C023I2 BE 2013C023 C BE2013C023 C BE 2013C023C BE 2013C023 C BE2013C023 C BE 2013C023C BE 2013C023 I2 BE2013C023 I2 BE 2013C023I2
Authority
BE
Belgium
Prior art keywords
glycopyrrolate
dry powder
formulation
copd
excipient
Prior art date
Application number
BE2013C023C
Other languages
English (en)
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of BE2013C023I2 publication Critical patent/BE2013C023I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BE2013C023C 2000-04-07 2013-03-26 BE2013C023I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (fr) 2000-04-07 2001-04-09 Traitement de troubles respiratoires
EP01966751.8A EP1267866B2 (fr) 2000-04-07 2001-04-09 Traitement de troubles respiratoires

Publications (1)

Publication Number Publication Date
BE2013C023I2 true BE2013C023I2 (fr) 2020-06-24

Family

ID=9889490

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C023C BE2013C023I2 (fr) 2000-04-07 2013-03-26

Country Status (25)

Country Link
US (3) US7229607B2 (fr)
EP (3) EP1267866B2 (fr)
JP (1) JP5042426B2 (fr)
CN (3) CN101181263B (fr)
AT (1) ATE330585T2 (fr)
AU (2) AU2004242450B2 (fr)
BE (1) BE2013C023I2 (fr)
BR (1) BR0109875A (fr)
CA (1) CA2405705C (fr)
CY (1) CY1105120T1 (fr)
DE (1) DE60120936T3 (fr)
DK (1) DK1267866T4 (fr)
ES (2) ES2266242T5 (fr)
GB (1) GB0008660D0 (fr)
HK (1) HK1050846B (fr)
HU (2) HU230958B1 (fr)
IL (2) IL151791A0 (fr)
LU (2) LU92166I2 (fr)
MX (1) MXPA02009718A (fr)
NO (3) NO336142B1 (fr)
NZ (2) NZ521476A (fr)
PL (1) PL364024A1 (fr)
PT (1) PT1267866E (fr)
WO (1) WO2001076575A2 (fr)
ZA (1) ZA200207420B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2002220857A1 (en) 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
ATE382335T1 (de) 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
CA2341952A1 (fr) * 2001-03-23 2002-09-23 Universite Laval Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
US20040146561A1 (en) 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
MXPA04008372A (es) * 2002-03-01 2004-11-26 Chiesi Farma Spa Formulacion superfina de formoterol.
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2534352A1 (fr) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Procede de production de proteines dans une levure
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20080312136A1 (en) * 2003-11-14 2008-12-18 Manzer Durrani Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions
DK1713471T3 (da) * 2004-02-06 2012-05-14 Meda Pharma Gmbh & Co Kg Kombination af anticholinergika og inhibitorer af phosphodiesterase type 4 til behandling af respiratoriske sygdomme
JP5524442B2 (ja) * 2004-02-06 2014-06-18 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
CN100569235C (zh) 2004-02-06 2009-12-16 Meda制药有限及两合公司 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
US20070185067A1 (en) * 2004-02-27 2007-08-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1737499A4 (fr) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1763344A1 (fr) * 2004-06-29 2007-03-21 Boehringer Ingelheim International GmbH Medicament pour l'inhalation comprenant un steroide et un anticholinergique
EP1616567A1 (fr) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
WO2006026502A1 (fr) * 2004-08-27 2006-03-09 The Dow Chemical Company Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
RU2420285C2 (ru) 2005-03-16 2011-06-10 Меда Фарма Гмбх Унд Ко.Кг Комбинация r,r-гликопирролата и монтелукаста для лечения респираторных заболеваний и фармацевтическая композиция на ее основе
EP1861361A1 (fr) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Sels de glycopyrronium et leur application thérapeutique
JP2009519970A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経口投与用製薬剤形の製造方法
PT2098248E (pt) * 2005-12-21 2012-08-27 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos, glucocorticóides e agonistas de beta 2 para o tratamento de doenças inflamatórias
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (fr) * 2006-03-17 2007-09-27 Oregon Health & Science University Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2009074662A2 (fr) * 2007-12-13 2009-06-18 Novartis Ag Composés organiques
CN101896165B (zh) * 2007-12-13 2013-07-17 诺瓦提斯公司 有机化合物
WO2009134524A2 (fr) 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Procédé et système permettant de traiter la bronchopneumopathie chronique obstructive au moyen d'administrations d'anticholinergiques par nébulisation
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
BRPI1011220B1 (pt) * 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CA2785349C (fr) 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Polytherapie destinee a la bronchopneumopathie chronique obstructive
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
MY156950A (en) 2009-12-23 2016-04-15 Chiesi Farma Spa Aerosol formulation for copd
KR20120106753A (ko) 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
KR101915241B1 (ko) * 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
PT2739268T (pt) 2011-08-01 2019-01-28 Univ Monash Método e formulação para inalação
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
RU2015146871A (ru) 2013-04-01 2017-05-10 Пулматрикс, Инк. Сухие порошки с тиотропием
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (fr) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Procédé de broyage de milieux pour la fabrication de composants pharmaceutiques actifs dans des propulseurs
EP3089735B1 (fr) 2013-12-30 2018-07-11 Chiesi Farmaceutici S.p.A. Stable solutions d'aerosol sous pression contenant de glykopyrronium bromide et formoterol
PL3191081T3 (pl) 2014-09-09 2020-09-07 Vectura Limited Formulacja zawierająca glikopirolan, sposób i urządzenie
NZ767295A (en) * 2014-09-15 2024-01-26 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (fr) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Compositions pharmaceutiques comprenant de l'arformotérol et du glycopyrronium
MX2017016331A (es) * 2015-06-15 2018-09-05 Qaam Pharmaceuticals Llc Sales de ácido graso de glicopirronio y métodos para elaborar las mismas.
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
SI0937041T1 (en) * 1996-11-11 2003-10-31 Christian R. Noe Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO1998031346A1 (fr) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation de particules pour inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
AU748867B2 (en) * 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
EP1102579B1 (fr) * 1998-08-04 2003-03-19 Jago Research Ag Formulations d'aerosol a usage medical
RO122660B1 (ro) * 1998-11-13 2009-11-30 Skypepharma Ag Pulbere inhalabilă uscată
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
WO2001008681A1 (fr) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methodes d'administration de compositions de glycopyrrolates
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 Henkel IP & Holding GmbH 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
CN1422154A (zh) 2003-06-04
NO2015024I1 (no) 2015-11-25
AU8930601A (en) 2001-10-23
BR0109875A (pt) 2004-07-20
ATE330585T2 (de) 2006-07-15
CN101181263A (zh) 2008-05-21
CA2405705C (fr) 2011-06-07
NZ521476A (en) 2004-10-29
PT1267866E (pt) 2006-10-31
NO2015024I2 (no) 2015-11-25
NZ535284A (en) 2006-04-28
PL364024A1 (en) 2004-11-29
ES2266242T3 (es) 2007-03-01
AU2004242450B2 (en) 2010-06-03
US20030068280A1 (en) 2003-04-10
AU2010200660B2 (en) 2012-04-19
NO2015025I1 (no) 2015-12-07
US7229607B2 (en) 2007-06-12
ES2266242T5 (es) 2016-10-04
AU2010200660A1 (en) 2010-03-11
ES2687751T3 (es) 2018-10-29
GB0008660D0 (en) 2000-05-31
DE60120936D1 (de) 2006-08-03
ZA200207420B (en) 2003-09-16
WO2001076575A3 (fr) 2002-03-28
JP5042426B2 (ja) 2012-10-03
NO20024708D0 (no) 2002-10-01
DK1267866T4 (en) 2016-10-03
CN1720995A (zh) 2006-01-18
HUS1900056I1 (hu) 2020-02-28
US7368104B2 (en) 2008-05-06
EP1449528B1 (fr) 2018-08-08
JP2003530344A (ja) 2003-10-14
HUP0301518A2 (hu) 2003-08-28
LU92166I2 (fr) 2014-03-13
EP1267866B2 (fr) 2016-07-20
US8029768B2 (en) 2011-10-04
NO20024708L (no) 2002-10-24
EP1267866B1 (fr) 2006-06-21
US20050019271A1 (en) 2005-01-27
AU2004242450A1 (en) 2005-01-20
NO336142B1 (no) 2015-05-26
WO2001076575A2 (fr) 2001-10-18
EP2193791A1 (fr) 2010-06-09
IL151791A (en) 2015-05-31
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
EP1449528A1 (fr) 2004-08-25
CA2405705A1 (fr) 2001-10-18
IL151791A0 (en) 2003-04-10
DK1267866T3 (da) 2006-10-23
HU230958B1 (hu) 2019-06-28
HK1050846B (zh) 2007-01-26
US20080220073A1 (en) 2008-09-11
EP1267866A2 (fr) 2003-01-02
CN1292745C (zh) 2007-01-03
HK1050846A1 (en) 2003-07-11
MXPA02009718A (es) 2003-05-27
CN101181263B (zh) 2011-07-06
DE60120936T3 (de) 2016-11-17
LU92393I2 (fr) 2015-11-02
DE60120936T2 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
BE2013C023I2 (fr)
MXPA02011311A (es) Composicion novedosa.
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
HUP0204136A2 (hu) Eljárások az interleukin-2 tüdőbe juttatására
CA2389349A1 (fr) Utilisation de composes organiques dans le traitement d'une maladie
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
WO2002015662A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
MY148125A (en) Compounds
AU5900601A (en) Novel process
HUP0401086A3 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
WO2003087049A3 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
AP2002002496A0 (en) Method and compositions for treating pulmonary diseases.
HUP0204391A3 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
AU2002259013A1 (en) Novel methods and compositions for delivering macromolecules to or via the respiratory tract
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
SI1257254T1 (sl) Farmacevtske oblike, ki vsebujejo antiholinergicno zdravilo za zdravljenje kronicne obstruktivne bolezni pljuc